Avadel pharmaceuticals to provide a company update and report fourth quarter and full year 2020 financial results, on march 9th

Dublin, ireland, feb. 23, 2021 (globe newswire) -- avadel pharmaceuticals plc (nasdaq: avdl), a company focused on developing ft218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, announced today that it will host a conference call and live webcast at 8:30 a.m. et on tuesday, march 9, 2021, to provide a company update and discuss the company's financial results for the fourth quarter and full year ended december 31, 2020.
AVDL Ratings Summary
AVDL Quant Ranking